Egetis Therapeutics
An integrated pharmaceutical company focusing on projects in late-stage development for commercialization for orphan drugs.
The company’s lead drug candidate emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. The drug holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU.
Latest Egetis Therapeutics News & Features
11 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze